BridgeBio Pharma, (Germany) Performance

BridgeBio Pharma, Relative Risk vs. Return Landscape

If you would invest  5,352  in BridgeBio Pharma on November 10, 2025 and sell it today you would lose (22.00) from holding BridgeBio Pharma or give up 0.41% of portfolio value over 90 days. BridgeBio Pharma is currently producing 0.0409% returns and takes up 3.0347% volatility of returns over 90 trading days. Put another way, 27% of traded stocks are less volatile than BridgeBio, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.Assuming the 90 days horizon BridgeBio Pharma, is expected to generate 2.3 times less return on investment than the market. In addition to that, the company is 3.74 times more volatile than its market benchmark. It trades about 0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

BridgeBio Pharma, Target Price Odds to finish over Current Price

Assuming the 90 days horizon BridgeBio Pharma has a beta of -1.14. This suggests Additionally BridgeBio Pharma has an alpha of 0.0959, implying that it can generate a 0.0959 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).

Predictive Modules for BridgeBio Pharma,

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BridgeBio Pharma,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Hype Prediction Low Estimated High 50.20 53.23 56.26 Details

Intrinsic Valuation Low Real High 44.78 47.81 58.63 Details

BridgeBio Pharma, Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BridgeBio Pharma, is not an exception. The market had few large corrections towards the BridgeBio Pharma,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BridgeBio Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BridgeBio Pharma, within the framework of very fundamental risk indicators.

BridgeBio Pharma, Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BridgeBio Pharma, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BridgeBio Pharma, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.

BridgeBio Pharma, Fundamentals Growth

When running BridgeBio Pharma,'s price analysis, check to measure BridgeBio Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma, is operating at the current time. Most of BridgeBio Pharma,'s value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma,'s price. Additionally, you may evaluate how the addition of BridgeBio Pharma, to your portfolios can decrease your overall portfolio volatility.